Toxicology – Succimer (DMSA)

Core Concept

Succimer (dimercaptosuccinic acid; DMSA) is an orally active dithiol chelating agent used primarily for lead poisoning.

It can also chelate:

• Arsenic
• Inorganic mercury

Compared with older parenteral chelators such as dimercaprol (BAL), succimer is generally easier to administer and better tolerated.

Chelation is only one part of treatment. For lead poisoning in particular:

Identification and permanent removal of the exposure source are essential.

Mechanism of Action

Succimer contains sulfhydryl (–SH) groups capable of binding certain metals.

Conceptually:

Metal + succimer → metal–succimer complex → urinary excretion

Chelation decreases the amount of biologically available metal capable of interacting with:

• Enzymes
• Cellular proteins
• Sulfhydryl-containing molecules
• Other physiologic targets

Metals Chelated

Succimer has clinically useful binding activity for:

• Lead
• Arsenic
• Inorganic mercury

Its effectiveness depends strongly on the specific metal, chemical species, exposure pattern, timing, symptoms, and distribution into tissues.

Chelators are therefore not interchangeable.

Advantages of Succimer

Important advantages include:

• Oral administration
• Generally favorable tolerability
• Effective enhancement of urinary lead excretion
• Less depletion of some essential trace elements than older nonspecific chelators
• No painful deep IM administration, unlike BAL
• Useful in many patients who do not require parenteral chelation

Lead Poisoning

Lead is the best-established toxicologic indication for succimer.

Lead interferes with multiple physiologic processes, including:

• Heme synthesis
• Neurologic function
• Renal function
• Gastrointestinal function
• Hematopoiesis

Children are particularly vulnerable to lead-associated neurodevelopmental injury.

Clinical Features of Lead Toxicity

Possible manifestations include:

• Abdominal pain
• Constipation
• Irritability
• Fatigue
• Headache
• Cognitive or behavioral changes
• Peripheral neuropathy
• Anemia
• Hypertension
• Renal dysfunction

Severe poisoning may produce:

• Encephalopathy
• Ataxia
• Seizures
• Altered consciousness
• Coma

Blood Lead Level

A venous blood lead level (BLL) is the principal laboratory measurement used to assess lead exposure.

Capillary screening can be useful, but an elevated screening result generally requires appropriate venous confirmation because environmental contamination can falsely elevate capillary measurements.

Chelation Thresholds – Important Modernization

The older source’s approach to children with BLLs between approximately 20–45 µg/dL is outdated.

Modern pediatric management does not routinely recommend succimer simply because a child has a moderately elevated BLL.

Chelation decisions depend on:

• Confirmed venous BLL
• Symptoms
• Age
• Exposure source
• Clinical severity
• Ability to eliminate ongoing exposure
• Specialist/public-health guidance

For significant pediatric lead poisoning, succimer remains an important oral chelator, particularly around the traditionally recognized higher chelation range, but current protocols should be followed rather than automatically treating lower concentrations.

Why Lower-Level Chelation Is Not Routine

Clinical studies showed that lowering moderately elevated blood lead concentrations with succimer did not reliably improve neurodevelopmental outcomes.

Therefore:

Reducing the laboratory number is not equivalent to reversing established neurodevelopmental injury.

The most important intervention at lower exposure levels is prevention of continued exposure.

Source Control

Before and during chelation, identify possible lead sources such as:

• Lead-based paint or contaminated dust
• Contaminated soil
• Occupational take-home exposure
• Certain imported products
• Traditional remedies or cosmetics
• Contaminated cookware or ceramics
• Retained lead-containing foreign material

Chelation without exposure control can produce only temporary improvement.

Severe Lead Poisoning

Succimer is not the preferred sole therapy for lead encephalopathy or other immediately life-threatening lead poisoning.

Severe neurologic toxicity may require parenteral chelation, traditionally involving agents such as:

• Calcium disodium EDTA (CaNa₂EDTA)
• Dimercaprol (BAL) in selected severe cases

Management should involve a medical toxicologist or poison center.

Do Not Confuse EDTA Preparations

For lead chelation:

Calcium disodium EDTA (CaNa₂EDTA) is the therapeutic chelator.

Disodium EDTA (Na₂EDTA) is not interchangeable and can produce dangerous hypocalcemia.

Lead Rebound

Blood lead concentrations commonly increase again after chelation stops.

This can occur because lead stored in tissues and especially bone redistributes back into blood.

Therefore:

Post-chelation rebound does not automatically mean that treatment failed.

Serial BLL measurements are required.

Persistent or Recurrent Lead Elevation

When BLL rises after treatment, consider:

• Continued environmental exposure
• Incomplete source removal
• Redistribution from tissue stores
• Large chronic body burden
• Retained lead-containing material

The cause should be investigated before reflexively repeating chelation.

Succimer Does Not Remove Lead Equally From All Compartments

Succimer primarily lowers lead in:

• Blood
• Accessible soft-tissue compartments

It is much less effective at rapidly removing large stores from bone.

This explains why chronic poisoning may demonstrate rebound after treatment.

Arsenic Poisoning

Succimer can bind arsenic and has been used for selected arsenic poisoning.

Acute arsenic toxicity may produce:

• Severe vomiting and diarrhea
• Abdominal pain
• Hypotension
• QT abnormalities
• Dysrhythmias
• Encephalopathy
• Acute kidney injury

Delayed manifestations can include:

• Peripheral neuropathy
• Bone-marrow abnormalities
• Skin and nail changes

Succimer in Arsenic Poisoning

Succimer is a potential oral chelator for selected patients, particularly once they can tolerate oral therapy.

For severe acute arsenic poisoning, other chelation strategies such as dimercaprol or DMPS, depending on circumstances and regional availability, may be considered.

The evidence base is less robust than for succimer in lead poisoning.

Arsenic Testing

Urinary arsenic is useful in assessing recent exposure.

However, total urinary arsenic can be misleading after consumption of seafood because relatively nontoxic organic arsenic compounds can substantially increase the total concentration.

When necessary:

Arsenic speciation helps distinguish toxicologically important inorganic forms from seafood-associated organic arsenicals.

Avoid Provoked Urine Testing

Administering a chelator and then measuring how much metal appears in urine is sometimes marketed as a way to diagnose “metal toxicity.”

This is not a validated approach.

Chelators naturally increase urinary metal excretion even in people without clinically significant poisoning.

Therefore:

Post-chelator or “provoked” urine testing should not be used to diagnose heavy-metal poisoning.

Mercury Poisoning

The role of succimer depends heavily on the chemical form of mercury.

Major forms include:

• Elemental mercury
• Inorganic mercury salts
• Organic mercury compounds such as methylmercury

Their absorption, distribution, target organs, and response to chelation differ substantially.

Elemental Mercury

Elemental liquid mercury is poorly absorbed through an intact gastrointestinal tract.

However, mercury vapor is readily absorbed through the lungs.

Significant inhalational exposure can produce:

• Cough
• Dyspnea
• Chemical pneumonitis
• Tremor
• Neuropsychiatric abnormalities
• Renal effects

Chelation may be considered for selected clinically important systemic exposures.

Inorganic Mercury

Inorganic mercury salts can produce:

• Severe gastrointestinal injury
• Renal toxicity
• Shock
• Systemic poisoning

Succimer or DMPS may be considered depending on severity, formulation, availability, and specialist recommendations.

Organic Mercury

Organic mercury compounds distribute extensively into the CNS.

Chelation decisions are more complicated, and succimer should not automatically be assumed to reverse established neurologic injury.

Specialist guidance is particularly important.

Urinary Mercury

Urinary mercury testing can be useful for certain elemental or inorganic mercury exposures.

However, interpretation depends on:

• Mercury species
• Timing
• Exposure history
• Symptoms

A high urine concentration after administration of a chelator does not itself establish mercury poisoning.

Renal Elimination

Succimer–metal complexes are predominantly eliminated through the kidneys.

Renal function should therefore be considered during treatment.

Significant renal impairment may alter:

• Chelator handling
• Metal-complex elimination
• Overall treatment strategy

Adverse Effects

Succimer is usually well tolerated.

Possible adverse effects include:

• Nausea
• Vomiting
• Diarrhea
• Abdominal discomfort
• Reduced appetite
• Rash
• Pruritus
• Headache

A characteristic sulfurous odor may occur.

Hepatic Effects

Transient increases in aminotransferases can occur.

Therefore, liver function should be assessed when clinically appropriate, particularly during repeated courses.

Marked or progressive abnormalities warrant reassessment.

Hematologic Effects

Rare hematologic abnormalities can occur, including:

• Neutropenia
• Other leukocyte abnormalities

CBC monitoring is therefore appropriate during therapeutic courses, especially repeated treatment.

Hypersensitivity

Rash and other hypersensitivity reactions can occur.

A documented serious hypersensitivity reaction to succimer is an important contraindication to re-exposure.

G6PD Deficiency

Older literature contains isolated reports of hemolysis in patients with G6PD deficiency.

This is not considered one of the dominant toxicities of succimer, but unexplained hemolysis during therapy should prompt appropriate investigation.

Essential Trace Elements

Succimer is more selective than some older chelators and generally causes less clinically important depletion of essential metals.

Nevertheless, describing it as having absolutely no effect on essential minerals would be too strong.

Long or repeated courses warrant appropriate clinical and laboratory monitoring.

Iron Interaction

Unlike dimercaprol, succimer does not have the same major concern regarding concurrent iron exposure.

This is relevant because dimercaprol should not be used for iron poisoning and may form harmful complexes with iron.

Succimer itself is also not an antidote for iron poisoning.

Pregnancy

The historical FDA Category C system is obsolete.

Chelation during pregnancy requires individualized assessment because both:

• Maternal metal toxicity
• Chelating therapy

may have implications for the fetus.

Severe maternal poisoning may warrant treatment despite potential drug risks, ideally with toxicology and obstetric consultation.

Chelation Does Not Reverse Established Damage

An important general principle:

Removing circulating metal does not guarantee reversal of established organ injury.

For example, succimer can lower BLL but cannot reliably reverse:

• Established neurodevelopmental injury from lead
• Advanced neuropathy
• Established CNS damage from mercury
• Severe tissue injury already produced by arsenic

This reinforces the importance of early exposure prevention.

Monitoring During Succimer Therapy

Depending on the metal and clinical situation, monitoring may include:

• Confirmed metal concentration
• CBC
• Renal function
• Liver enzymes
• Clinical neurologic findings
• Gastrointestinal symptoms
• Evidence of continuing exposure

For lead poisoning, repeat venous BLLs are important after treatment because rebound can occur.

Repeat Chelation

Repeat courses should not be automatic.

Before repeating therapy, reassess:

• Current metal concentration
• Symptoms
• Exposure source
• Whether exposure has truly stopped
• Renal and hepatic function
• Previous response to chelation

Persistent elevation caused by continued exposure will recur unless the source is eliminated.

Important Modernization of the Older Source

• Succimer is an oral dithiol chelator used primarily for lead poisoning.
• It also has activity against arsenic and inorganic mercury, although evidence and indications are less standardized.
• Chelation increases urinary excretion of metal but does not automatically reverse established tissue injury.
• A confirmed venous BLL should guide lead management.
• Routine chelation of children merely for moderately elevated BLLs below the usual chelation range is no longer recommended.
• Environmental/source control is fundamental and may be more important than chelation for lower-level lead exposure.
• Severe lead encephalopathy generally requires specialist-directed parenteral chelation, rather than succimer alone.
• Blood lead commonly rebounds after succimer because tissue and bone stores redistribute into blood.
• Rebound should prompt evaluation for both redistribution and ongoing exposure.
• Arsenic speciation may be needed because seafood can markedly elevate total urinary arsenic without representing dangerous inorganic arsenic exposure.
• Provoked urine metal testing after chelation is not a valid diagnostic strategy.
• Mercury management depends on whether exposure involves elemental, inorganic, or organic mercury.
• Succimer is generally well tolerated but can cause GI symptoms, rash, hepatic enzyme elevation, and rare hematologic abnormalities.
• Historical FDA pregnancy categories are obsolete.
• Exact chelation regimens and decisions about repeat courses should follow current poison-center, medical-toxicology, or specialty guidance.

Key Points

• Succimer contains sulfhydryl groups that bind selected metals → metal–succimer complexes → urinary elimination.
• Its best-established role is oral chelation of clinically significant lead poisoning.
• Succimer may also be used for selected arsenic and mercury poisoning.
• It is not the preferred sole treatment for severe lead encephalopathy.
• Removing the exposure source is essential; chelation without source control commonly results in recurrent elevation.
• Blood lead can rebound after treatment because lead redistributes from tissue and bone stores.
• Lowering BLL does not necessarily reverse established neurologic or developmental injury.
• Avoid using post-chelator “provoked” urine testing to diagnose metal poisoning.
• The chemical form of mercury matters when deciding whether chelation is appropriate.
• Monitor blood counts, hepatic function, renal function, clinical response, and the appropriate metal concentration during treatment.